Table 1. General characteristics of the HIV-infected patients (n = 70).
| Global (n = 70) | HIV-monoinfected patients (n = 20) | HIV/HVC coinfected patients | |||
|---|---|---|---|---|---|
| Global (n = 50) | Chronic hepatitis (n = 25) | Liver cirrhosis (n = 25) | |||
| General characteristics | |||||
| Age (years) | 47 (42–49) | 46 (39–49) | 47 (43–50) | 47 (43–51) | 47 (43–49) |
| Sex male (n, %) | 59 (84) | 16 (80) | 43 (86) | 20 (80) | 23 (92) |
| Previous parenteral drug use (n, %) | 44 (63) | 12 (60) | 32 (64) | 14 (56) | 18 (72) |
| Evolution of the infection (years) | 22 (19–26) | 22 (19–24) | 22 (20–27) | 22 (20–26) | 22 (19–27) |
| HIV-related characteristics | |||||
| CD4+ T cell/mm3 at diagnosis | 150 (87–267) | 182 (107–416) | 146 (65–253) | 160 (73–258) | 145 (64–234) |
| CD4+ T cell/mm3 at inclusion | 342 (252–535) | 305 (193–473) | 359 (277–540) | 519 (321–661) * | 339 (229–380) * |
| CD4+ T cell increase from diagnosis until inclusion | 181 (57–295) | 85 (-53; +183) | 202 (111–334) | 288 (177–399) | 172 (55–221) |
| CDC C stage (n, %) | 36 (51) | 12 (60) | 24 (48) | 14 (56) | 10 (40) |
| Months with undetectable HIV load | 42 (17–72) | 49 (16–102) | 39 (18–62) | 24 (16–60) | 48 (18–55) |
| Protease inhibitor—based HAART (n, %) | 38 (54) | 11 (55) | 27 (54) | 13 (52) | 14 (56) |
| HCV-related characteristics | |||||
| Liver stiffness (kPa) | 15 (10–27) | 10 (9–12) ** | 27 (17–33) ** | ||
| HCV genotype 1 or 4 (n, %) | 32 (64) | 18 (72) | 14 (56) | ||
| HCV viral load (x 1000) at inclusion | 2574 (401–4640) | 3130 (643–4404) | 2514 (572–4948) | ||
Quantitative variables are expressed as median (interquartile range).
* p = 0,003 HIV/HCV coinfected patients with cirrhosis vs HIV/HCV coinfected patients with chronic hepatitis.
** p < 0,001 HIV/HCV coinfected patients with cirrhosis vs HIV/HCV coinfected patients with chronic hepatitis.